After several regulatory delays, Mannkind ($MNKD) finally got its Afrezza inhaled insulin past the FDA. With the help of marketing partner Sanofi ($SNY), the company posted Afrezza shipments worth $13 million in the first half of the year, though it still experienced a net loss of $28.9 million in Q2. Looking forward, the company aims to use its delivery tech to treat a variety of conditions, potentially including pain, pulmonary-related diseases, central nervous system diseases and nicotine addition. One advantage of the inhaled administration pathway is that drugs don't come into contact with the liver, which is helpful for those that are toxic to that organ. "We're trying to build a portfolio of probably about four to 6 products that we will pursue," Mannkind CEO Hakan Edstrom said. "Not all of them will be successful, but you've got to start and then hope that you reach all the way through regulatory approval to the market." More